Oncolytics Biotech Inc. (ONCY) News
Follow Oncolytics Biotech Inc. (ONCY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Oncolytics Biotech: Publication Shows Pelareorep Converts ‘Cold’ Liver Tumors to Immune—Active, Supporting its Backbone Immunotherapy Role
Oncolytics Biotech announced published data showing pelareorep converts immunologically inactive liver tumors into an immune—active state that may enable immunotherapy.Key Highlights:Original SEC Filing: ONCOLYTICS BIOTE
REGULATION | Sep 29, 2026, 01:43 PM UTC
L
Oncolytics Biotech Inc. (ONCY) Publishes Data Showing Pelareorep Primes Liver Tumors for Immunotherapy
Oncolytics Biotech Inc. reported PNAS-published preclinical data that pelareorep converted immunologically inactive liver tumors to an active state, increasing PD-L1, ICOSL, and CD8+ T cells, potentially enabling respons
NEWS | Sep 29, 2026, 01:38 PM UTC
L
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype that will respond to immune-based interventionSAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- On
NEWS | Sep 29, 2026, 01:38 PM UTC
L
Oncolytics reports accelerated enrollment, expects Part A interim REO 033 data by year-end 2026
Oncolytics reported that substantially all REO 033 sites are activated and expects interim Part A data by year-end 2026.Key Highlights:Original SEC Filing: ONCOLYTICS BIOTECH INC [ ONCY ] - 8-K - Sep. 28, 2026This is an
REGULATION | Sep 28, 2026, 01:35 PM UTC
L
Oncolytics Biotech Inc. (ONCY) Targets Year-End Interim Data for REO 033
Oncolytics Biotech Inc. said substantially all REO 033 sites are activated, multiple patients are enrolled, and it expects to have sufficient Part A data for an interim update by year-end 2026. FDA alignment suggests a p
REGULATION | Sep 28, 2026, 01:32 PM UTC
L
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on studyCompany expects to have sufficient Part A data to provide an interim clinical update by year-end 2026FDA alignm
NEWS | Sep 28, 2026, 01:32 PM UTC
L
Oncolytics announces positive preclinical data for pelareorep combination
The company said pelareorep activity was maintained when combined with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. The source cites an original SEC filing and describes the results as preclinical.
EQUITY | Sep 10, 2026, 12:24 PM UTC
L
ONCY - Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer - Click
ONCY - Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
EQUITY | Sep 10, 2026, 12:15 PM UTC
L
Onconvex (ONCY) price target cut from $10 to $5, keeps Buy
Hammerstone MarketTalk cuts Onconvex (ONCY) price target from $10 to $5 while maintaining a Buy rating at HCW, per the note.
EQUITY | Aug 19, 2026, 12:21 PM UTC
M
Oncolytics Biotech aligns with FDA on registrational path
Oncolytics Biotech (ONCY) says it has aligned with the FDA on the registrational path for second-line RAS-mutant MSS colorectal cancer.
REGULATION | Aug 18, 2026, 01:03 PM UTC
L
Oncolytics announces FDA Fast Track designation for pelareorep
Oncolytics announced that...
REGULATION | Jul 20, 2026, 01:03 PM UTC